Bioavailability Containment Contamination Contract Manufacturing 
Pharmaceutical Technology
APRIL 12, 2023
The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment. Currently mostly outsourced, there are signs that CMOs are beginning to make investments in containment capabilities, to capture emerging opportunities.
Pharmaceutical Technology
JUNE 14, 2023
This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Premium specialized equipment is necessary because high containment facilities call for the separation of the operator from the product.
Expert insights. Personalized for you.
130 
Let's personalize your content